(Q45662172)

15 December 2017

Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours (English)

1 reference

15 December 2017

1 reference

ChEBI release 2020-05-28

1 reference

Sven Wind

1

1 reference

15 December 2017

Marion Schmid

2

1 reference

15 December 2017

Julia Erhardt

3

1 reference

15 December 2017

Rainer-Georg Goeldner

4

1 reference

15 December 2017

Peter Stopfer

5

1 reference

15 December 2017

1 December 2013

1 reference

Clinical Pharmacokinetics

15 December 2017

1 reference

15 December 2017

52

1 reference

15 December 2017

1101-1109

1 reference

15 December 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-013-0091-4

15 December 2017

0 references

cites work

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Confidence interval criteria for assessment of dose proportionality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0091-4

Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva).

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23813493

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40262-013-0091-4

1 reference

Dimensions Publication ID

15 December 2017

1019821429

0 references

Fatcat ID

release_sb4pic4fcbhlrd6pjashiqxyom

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sb4pic4fcbhlrd6pjashiqxyom

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference